Pregabalin for the management of partial epilepsy

Philippe Ryvlin1, Emilio Perucca2, Sylvain Rheims11Service de Neurologie et d&rsquo;Epileptologie, H&ocirc;pital Neurologique, Hospices Civils de Lyon, Universit&eacute; Lyon 1, INSERM U821 and CTRSID&Eacute;E, Lyon, France; 2Clinical Trial Centre, Institute of Neurol...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Philippe Ryvlin, Emilio Perucca, Sylvain Rheims
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2008
Materias:	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/9ccf453834e9493c9bcfa7db6de0d76d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9ccf453834e9493c9bcfa7db6de0d76d
record_format	dspace
spelling	oai:doaj.org-article:9ccf453834e9493c9bcfa7db6de0d76d2021-12-02T02:43:14ZPregabalin for the management of partial epilepsy1176-63281178-2021https://doaj.org/article/9ccf453834e9493c9bcfa7db6de0d76d2008-11-01T00:00:00Zhttp://www.dovepress.com/pregabalin-for-the-management-of-partial-epilepsy-a2634https://doaj.org/toc/1176-6328https://doaj.org/toc/1178-2021Philippe Ryvlin1, Emilio Perucca2, Sylvain Rheims11Service de Neurologie et d&rsquo;Epileptologie, H&ocirc;pital Neurologique, Hospices Civils de Lyon, Universit&eacute; Lyon 1, INSERM U821 and CTRSID&Eacute;E, Lyon, France; 2Clinical Trial Centre, Institute of Neurology IRCCS C Mondino Foundation, and Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyAbstract: Pregabalin is one of the latest antiepileptic drugs introduced for the treatment of partial epilepsy. Its efficacy and safety as adjunctive therapy in refractory partial epilepsy have been established in four double-blind placebo-controlled trials (n = 1396) and 4 long-term open-label studies (n = 1480). In 3 fixed-dose trials, the proportion of patients with a &ge;50% reduction in seizure frequency across the effective dose-range (150&ndash;600 mg/day) ranged between 14% and 51%, with a clear dose-response relationship. Suppression of seizure activity could be demonstrated as early as day 2. The most frequently reported CNS-related adverse events included dizziness, somnolence, ataxia and fatigue, were usually mild or moderate, and tended to be dose related. In long-term studies, weight gain was reported as an adverse event by 24% of patients. When pregabalin dose was individualized to according to response within the 150 to 600 mg/day dose range, tolerability was considerably improved compared with use of a high-dose, fixed-dose regimen (600 mg/day) without titration. In long-term studies up to 4 years, no evidence of loss efficacy was identified. During the last year on pregabalin, 3.7% of patients were seizure-free. Pregabalin appears to be a useful addition to the therapeutic armamentariun for the management of refractory partial epilepsy.Keywords: pregabalin, antiepileptic drugs, adjunctive therapy, partial seizures, efficacy, tolerability, clinical trials Philippe RyvlinEmilio PeruccaSylvain RheimsDove Medical PressarticleNeurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol 2008, Iss Issue 6, Pp 1211-1224 (2008)
institution	DOAJ
collection	DOAJ
language	EN
topic	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Philippe Ryvlin Emilio Perucca Sylvain Rheims Pregabalin for the management of partial epilepsy
description	Philippe Ryvlin1, Emilio Perucca2, Sylvain Rheims11Service de Neurologie et d&rsquo;Epileptologie, H&ocirc;pital Neurologique, Hospices Civils de Lyon, Universit&eacute; Lyon 1, INSERM U821 and CTRSID&Eacute;E, Lyon, France; 2Clinical Trial Centre, Institute of Neurology IRCCS C Mondino Foundation, and Clinical Pharmacology Unit, Department of Internal Medicine and Therapeutics, University of Pavia, Pavia, ItalyAbstract: Pregabalin is one of the latest antiepileptic drugs introduced for the treatment of partial epilepsy. Its efficacy and safety as adjunctive therapy in refractory partial epilepsy have been established in four double-blind placebo-controlled trials (n = 1396) and 4 long-term open-label studies (n = 1480). In 3 fixed-dose trials, the proportion of patients with a &ge;50% reduction in seizure frequency across the effective dose-range (150&ndash;600 mg/day) ranged between 14% and 51%, with a clear dose-response relationship. Suppression of seizure activity could be demonstrated as early as day 2. The most frequently reported CNS-related adverse events included dizziness, somnolence, ataxia and fatigue, were usually mild or moderate, and tended to be dose related. In long-term studies, weight gain was reported as an adverse event by 24% of patients. When pregabalin dose was individualized to according to response within the 150 to 600 mg/day dose range, tolerability was considerably improved compared with use of a high-dose, fixed-dose regimen (600 mg/day) without titration. In long-term studies up to 4 years, no evidence of loss efficacy was identified. During the last year on pregabalin, 3.7% of patients were seizure-free. Pregabalin appears to be a useful addition to the therapeutic armamentariun for the management of refractory partial epilepsy.Keywords: pregabalin, antiepileptic drugs, adjunctive therapy, partial seizures, efficacy, tolerability, clinical trials
format	article
author	Philippe Ryvlin Emilio Perucca Sylvain Rheims
author_facet	Philippe Ryvlin Emilio Perucca Sylvain Rheims
author_sort	Philippe Ryvlin
title	Pregabalin for the management of partial epilepsy
title_short	Pregabalin for the management of partial epilepsy
title_full	Pregabalin for the management of partial epilepsy
title_fullStr	Pregabalin for the management of partial epilepsy
title_full_unstemmed	Pregabalin for the management of partial epilepsy
title_sort	pregabalin for the management of partial epilepsy
publisher	Dove Medical Press
publishDate	2008
url	https://doaj.org/article/9ccf453834e9493c9bcfa7db6de0d76d
work_keys_str_mv	AT philipperyvlin pregabalinforthemanagementofpartialepilepsy AT emilioperucca pregabalinforthemanagementofpartialepilepsy AT sylvainrheims pregabalinforthemanagementofpartialepilepsy
_version_	1718402238836113408

Pregabalin for the management of partial epilepsy

Ejemplares similares